Barlow’s Research Roundup: Bank analyst warns investors to be selective, recommends these stocks

BMO bank analyst Sohrab Movahedi summarizes the first half of the year and warns investors of the need to be selective within ...
The Lancet

[177 Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival. Efficacy and harms results support the use of [177Lu]Lu-edotreotide in early ...